Noema Pharma Announces First Patient Dosed in Phase 2a Study of NOE-115, a First-In-Class Investigational Therapy for the Treatment of Vasomotor Symptoms and Additional Symptoms Associated with Menopause
May 22, 2024 08:00 ET
|
Noema Pharma AG
BASEL, Switzerland, May 22, 2024 (GLOBE NEWSWIRE) -- Noema Pharma AG, a clinical-stage biotech company targeting debilitating neuroscience-based disorders, today announced the first patient has been...
Noema Pharma to Present at Two Upcoming Conferences
January 03, 2024 08:00 ET
|
Noema Pharma AG
BASEL, Switzerland, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, today announced that members of...
Noema Pharma Appoints Robert Lasser, M.D., as Chief Medical Officer
November 15, 2023 08:00 ET
|
Noema Pharma AG
BASEL, Switzerland, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, today announced Robert Lasser,...
Noema Pharma Appoints Ilise Lombardo, M.D., as Chief Executive Officer
June 21, 2023 07:00 ET
|
Noema Pharma AG
BASEL, Switzerland, June 21, 2023 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, today announced the appointment of...
Noema Pharma to Present at BioEquity Europe 2023
May 09, 2023 07:00 ET
|
Noema Pharma AG
BASEL, Switzerland, May 09, 2023 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, today announced that senior members...